A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus.

A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus.

OBJECTIVE:Evidence suggests that chronic subclinical inflammation plays an important role in the pathogenesis of type 2 diabetes (T2DM). Circulating levels of interleukin (IL)-18 appear to be associated with a number of micro- and macrovascular comorbidities of obesity and T2DM. This study was desig...

Full description

Bibliographic Details
Main Authors: Elizabeth A McKie, Juliet L Reid, Prafull C Mistry, Stephen L DeWall, Lee Abberley, Philip D Ambery, Blas Gil-Extremera
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4773233?pdf=render

Internet

http://europepmc.org/articles/PMC4773233?pdf=render

Similar Items